Monitor for future disclosures on Yu Ding's capital strategy given the company's $4M market cap and likely funding needs; watch for potential Asia-focused partnerships or financings given new executives' regional expertise
Price Chart
Executive Summary
Indaptus Therapeutics announced the resignation of CFO Nir Sassi and the immediate appointment of Yu Ding as new CFO, along with the appointment of Qinglai Lu to the Board and Audit Committee. The leadership changes appear planned, with no disclosed disagreements, and bring fresh financial and Asia-Pacific market expertise to the company.
Key Facts
- CFO Nir Sassi resigned effective April 1, 2026, with no disclosed disagreement with the company
- Yu Ding appointed as new CFO effective immediately, bringing 20+ years of experience from CFO roles at Shanghai and Hong Kong-listed auto firms
- Qinglai Lu appointed to Board of Directors (effective April 8, 2026) and Audit Committee, with extensive finance and Web3 investment experience in Asia-Pacific
- Matthew McMurdo resigned from Audit Committee concurrent with Lu's appointment
- No compensation details or employment agreements filed with this 8-K
Financial Impact
No immediate financial impact disclosed; leadership transition may influence future capital raising and Asia strategy
Risk Factors
- Execution risk during CFO transition at a micro-cap biotech with limited resources
- Potential distraction from R&D priorities during leadership change
- No immediate insight into compensation costs for new executives
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 4 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 8-K Filing (Primary) | 0001493152-26-015079 |
| Document: 0001493152-26-015079-index-headers.html | 0001493152-26-015079 |
| Document: 0001493152-26-015079-index.html | 0001493152-26-015079 |
| Document: 0001493152-26-015079.txt | 0001493152-26-015079 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Sep 10, 2026 22d ago | 8-K | $2.56 $3.93 | ▼ −53.52% | ▼ −52.89% | $2.33 (+8.98%) |
Sep 4, 2026 27d ago | 424B5 | $1.85 $3.64 | ▼ −96.76% | ▼ −97.88% | $2.33 (−25.95%) |
Sep 1, 2026 4w ago | 8-K | $1.13 $2.08 | ▼ −84.07% | ▼ −83.99% | $2.33 (−106.19%) |
Aug 26, 2026 5w ago | EFFECT | $1.14 $1.17 | ▼ −2.63% | ▼ −2.75% | $2.33 (−104.39%) |
Aug 17, 2026 6w ago | S-3 | $0.9361 $1.10 | ▼ −16.97% | ▼ −17.18% | $2.33 (−148.91%) |
Aug 13, 2026 7w ago | 8-K | $1.06 $1.38 | ▲ +30.19% | ▲ +32.15% | $2.33 (+119.81%) |
Jul 20, 2026 10w ago | EFFECT | $2.46 $2.61 | ▼ −6.10% | ▼ −6.52% | $2.33 (+5.28%) |
Jun 26, 2026 13w ago | S-3 | $3.06 $2.85 | ▲ +6.86% | ▲ +8.25% | $2.33 (+23.86%) |
Jun 24, 2026 14w ago | 8-K | $3.26 $2.94 | ▲ +9.82% | ▲ +11.38% | $2.33 (+28.53%) |
May 15, 2026 20w ago | 8-K | $1.59 $1.22 | ▲ +23.27% | ▲ +24.23% | $2.33 (−46.54%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access